Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04621929 · ClinicalTrials.gov registry record · Phase 2
Phentermine/Topiramate for Uric Acid Stones
A Phase 2 study, sponsored by University of Florida.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT04621929: Completed Phase 2 study, sponsored by University of Florida.
NCT04621929 is a Phase 2 study that has completed, run by University of Florida. The registered enrollment target is 19 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04621929, a Phase 2 study, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
The investigator proposes an 18 month, feasibility pilot study, randomizing obese and diabetic individuals with pure uric acid nephrolithiasis (UAN) or mixed calcium oxalate (CO) UAN to either phentermine/topiramate or a pragmatic control group who will remain on their standard medication regimen (citrate salts, allopurinol, diet, etc.).
Primary Outcome
Stone perimeter within each cut of CT image was outlined using semiautomated volume tool (region of interest pen tool, CT software "Visage Imaging") and tallied to calculate stone volume (mm\^3) for each individual stone and recorded from right and left kidney from all study participants at baseline CT and at end of study CT (18 months)
Interventions
- DRUG Phentermine / Topiramate Oral Product
- COMBINATION_PRODUCT Citrate Salts, Allopurinol, Diet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2021-03-31 |
| Est. Completion | 2024-11-14 |
| Phase | Phase 2 |
What the finished NCT04621929 record still lists
NCT04621929 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% lower).
The record links to 0 conditions, and to 2 interventions - of which Phentermine / Topiramate Oral Product is the first listed.
NCT04621929 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04621929 about?
NCT04621929 is a clinical study titled "Phentermine/Topiramate for Uric Acid Stones". The investigator proposes an 18 month, feasibility pilot study, randomizing obese and diabetic individuals with pure uric acid nephrolithiasis (UAN) or mixed calcium oxalate (CO) UAN to either phentermine/topiramate or a pragmatic control group who will remain on their standard medication regimen (c...
What is the current status of trial NCT04621929?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2021-03-31. Estimated completion is 2024-11-14.
What interventions are being tested in trial NCT04621929?
The interventions under investigation include: Phentermine / Topiramate Oral Product (DRUG), Citrate Salts, Allopurinol, Diet (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT04621929?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04621929's enrollment target sits among peer trials
19 1894th of 2000 higher than 103 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI